The potential of pharmacogenetics in the treatment of epilepsy
- 1 March 2006
- journal article
- review article
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 10 (2) , 57-65
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProceedings of the National Academy of Sciences, 2004
- Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory EpilepsyEpilepsia, 2003
- Association of Multidrug Resistance in Epilepsy with a Polymorphism in the Drug-Transporter GeneABCB1New England Journal of Medicine, 2003
- Mechanisms of antiepileptic drug resistanceCurrent Opinion in Neurology, 2003
- Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsyBrain, 2002
- Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory EpilepsyEpilepsia, 2001
- Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProceedings of the National Academy of Sciences, 2000
- Patients with Refractory SeizuresNew England Journal of Medicine, 1999
- Multidrug Resistance‐Related Transport Proteins in Isolated Human Brain Microvessels and in Cells Cultured from These IsolatesJournal of Neurochemistry, 1998
- Update on the Mechanism of Action of Antiepileptic DrugsEpilepsia, 1996